Literature DB >> 2458145

Clinical and genetic heterogeneity in black patients with homozygous beta-thalassemia from the southeastern United States.

J M Gonzalez-Redondo1, T A Stoming, K D Lanclos, Y C Gu, A Kutlar, F Kutlar, T Nakatsuji, B Deng, I S Han, V C McKie.   

Abstract

The presence of various substitutions and deletions resulting in beta-thalassemia was studied in 19 black patients with homozygous beta-thalassemia and in numerous relatives; all patients were from Georgia, South Carolina, and Alabama. Methodology included gene mapping, amplification of genomic DNA with Taq polymerase, identification of known nucleotide substitutions or a single nucleotide deletion through hybridization with synthetic oligonucleotides, cloning and sequencing of a beta-globin gene, and sequencing of amplified genomic DNA. Of the 38 chromosomes tested, 21 (55%) had the A----G substitution at nt -29, eight (21%) had the C----T substitution at nt -88, three (8%) had the substitution at codon 24, while one each of the following abnormalities were also detected: frameshift at codon 6, a C----A mutation at nt 848 of the beta IVS-II (new), an A----T mutation at codon 61 (new), a deletion of 1.35 kilobases including the 5' end of beta, a Ggamma(Agamma delta beta)(0)-thalassemia, and one thalassemia determinant that remained unidentified. The C----A mutation at nt 848 of IVS-II occurred at a position 3 nucleotides 5' to the third exon, adjacent to the invariant AG dinucleotide of the acceptor sequence. The A----T mutation in codon 61 (AAG----TAG) resulted in the creation of a stop codon and thus in beta(0)-thalassemia. The various mutations occurred on chromosomes with different haplotypes; however, chromosomes with a specific mutation but with different haplotypes belonged to one specific framework, which suggested that crossovers were responsible for these different types. Hemoglobin (Hb) F levels were generally high (55% to 75% with 98.5% in one patient with beta(0)/beta(0)); a few patients with specific haplotypes and an alpha-thalassemia-2 heterozygosity had a lower Hb F level. The Ggamma in the Hb F was consistently high when the C----T mutation occurred at nt -158 to the Cap site of the Ggamma-globin gene; seven patients with +/+ at this site had an average Ggamma of 73.8%, eight patients with +/- had 64.8%, and one patient with -/- had 34.2%. Variations in hematologic values and in Hb F, Ggamma, and Hb A2 levels of relatives with a beta-thalassemia heterozygosity depended to some extent on the types of mutations or deletions and on the haplotypes of the chromosomes with the beta-thalassemia determinant.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458145

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Beta-thalassaemia: molecular pathogenesis and clinical variability.

Authors:  A E Kulozik
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

2.  Fetal hemoglobin in normal adults and beta-thalassemia heterozygotes.

Authors:  A Kutlar; F Kutlar; L G Gu; S M Mayson; T H Huisman
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

3.  The linkage of Hb Valletta [alpha 2 beta 287(f3)Thr----Pro] and Hb F-Malta-I [alpha 2G gamma 2117(G19)His----Arg] in the Maltese population.

Authors:  F Kutlar; A E Felice; J L Grech; W H Bannister; A Kutlar; J B Wilson; B B Webber; H Y Hu; T H Huisman
Journal:  Hum Genet       Date:  1991-04       Impact factor: 4.132

4.  Compound heterozygosity for a beta zero-thalassemia (frameshift codons 38/39; -C) and a nondeletional Swiss type of HPFH (A----C at NT -110, G gamma) in a Czechoslovakian family.

Authors:  K Indrak; J Indrakova; F Kutlar; D Pospisilova; I Sulovska; E Baysal; T H Huisman
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

5.  Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin.

Authors:  R W Burlingame; R L Rubin
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

6.  A Czechoslovakian teenager with Hb E-beta zero-thalassemia [IVS-I-1 (G----A)] complicated by the presence of an alpha-globin gene triplication.

Authors:  K Indrak; Y J Fei; H W Li; E Baysal; V Brabec; H Fortova; J Cermak; T H Huisman
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

7.  Silencing of human fetal globin expression is impaired in the absence of the adult beta-globin gene activator protein EKLF.

Authors:  A C Perkins; K M Gaensler; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 8.  Hb F in sickle cell anemia.

Authors:  A D Adekile; T H Huisman
Journal:  Experientia       Date:  1993-01-15

9.  Hb Costa Rica or alpha 2 beta 2 77(EF1)His --> Arg: the first example of a somatic cell mutation in a globin gene.

Authors:  W E Rodriguez Romero; M Castillo; M A Chaves; G F Saenz; L H Gu; J B Wilson; E Baysal; N S Smetanina; J Y Leonova; T H Huisman
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

10.  Molecular basis of transfusion dependent beta-thalassemia major patients in Sabah.

Authors:  Lai Kuan Teh; Elizabeth George; Mei I Lai; Jin Ai Mary Anne Tan; Lily Wong; Patimah Ismail
Journal:  J Hum Genet       Date:  2013-12-26       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.